secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2026-08-14T19:11:19+00:00
Accession:  0001213900-26-089912
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Q2 2026 net income $1.3M vs $1.1M loss; revenue up 124% on NIT license
-----------------------------------------------------------------------------

- Net revenues $6.3M for Q2 2026 vs $2.8M in Q2 2025, driven by NIT license revenue recognition.
- Operating expenses fell to $2.1M from $3.0M; income from operations $3.8M vs $0.4M loss.
- Net income $1.3M ($0.02 EPS) vs net loss $1.1M (-$0.02 EPS); cash $2.8M at June 30, 2026.
- NIT exclusive license for Endari in US/Canada effective May 15, 2026; upfront payment and royalties recognized.
- Weighted-average shares 70.2M vs 63.9M in prior-year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/0001213900-26-089912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/ea0302099-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-089912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer